The regulations for this degree are to be read in conjunction with all other relevant statutes and regulations including the Academic Statutes and Regulations.

1 In order to be admitted to this degree, an applicant intending to complete 240 points must have:

a completed the requirements for the Bachelor of Pharmacy from this University with a Grade Point Average of 5.0 or higher, or have equivalent prior study

or

b completed the requirements for the Bachelor of Pharmacy from this University with a Grade Point Average of 5.0 or higher in 120 points above Stage III

or

c (i) completed the requirements for the Bachelor of Pharmacy from this University, or have equivalent prior study

and

(ii) passed 60 points in a relevant postgraduate certificate or postgraduate diploma (or 60 points of relevant 700 level courses) with a Grade Point Average of 5.0 or higher, provided that the postgraduate certificate or postgraduate diploma has not been awarded.

2 In order to be admitted to this degree, an applicant intending to complete 120 points must have completed the requirements for the Bachelor of Pharmacy (Honours) or the Postgraduate Diploma in Clinical Pharmacy from this University with a Grade Point Average of 5.0 or higher, or have equivalent prior study.

3 In order to be admitted to this degree an applicant must hold current registration as a pharmacist in New Zealand.

4 Equivalence in Regulation 1 and 2 will be determined by the University. Equivalence pertains to the standard as well as nature and level of study.

5 A student admitted to this degree under Regulation 1 must:

a pass courses with a total value of 240 points

and

b complete within the time limit specified in the General Regulations – Masters Degrees.

6 A student admitted to this degree under Regulation 2 must:

a pass courses with a total value of 120 points

and

b complete within the time limit specified in the General Regulations – Masters Degrees.

7 The total enrolment for this degree must not exceed 280 points for a student admitted under Regulation 1 or 160 points for a student admitted under Regulation 2.

8 A student enrolled for this degree must complete the requirements as specified in the Master of Clinical Pharmacy Schedule.

9 A student required to complete 240 points must achieve a Grade Point Average of 5.0 or higher in the first 120 points of this degree prior to enrolment in PHARMACY 796. If this Grade Point Average is not achieved, enrolment in the Master of Clinical Pharmacy cannot continue.

10 A student must complete the University of Auckland Academic Integrity course as specified in the Enrolment and Programme Regulations, Academic Integrity, of the University Calendar.

11 A student enrolled for this degree must carry out satisfactorily such practice activities as the Programme Director may require.

12 a The research portfolio or thesis is to be carried out under the guidance of a supervisor, appointed by the Programme Director.

b The research portfolio or thesis topic must be approved by the Programme Director prior to enrolment.

c The research portfolio or thesis is to embody the results obtained by the student in an investigation into an area of Pharmacy.

d Any practical work in connection with the thesis or research portfolio must be carried out within the University. However, the Programme Director may permit a student to carry out the work at an approved site outside the University for any periods or period considered necessary.

e The research portfolio or thesis must be completed and submitted in accordance with the General Regulations – Masters Degrees.

13 A student may apply to reassign courses passed for this degree to the Postgraduate Diploma in Clinical Pharmacy.

14 This degree may be awarded with Honours as specified in the General Regulations – Masters Degrees.

15 In exceptional circumstances the Programme Director may approve a variation to a student’s programme of study in accordance with the Enrolment and Programme Regulations.

16 These regulations and/or schedule have been amended with effect from 1 January 2025.